Alnylam and Kyowa Hakko Form Alliance for the Development and Commercialization of ALN-RSV01 in Asia
- ALN-RSV01, Alnylam's Lead RNAi Therapeutic, is in Phase II Clinical Development for Treatment of Respiratory Syncytial Virus (RSV) Infection - CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Alnylam ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results